

# Serum Uric Acid Levels and Risk for Vascular Diseases in Patients with Metabolic Syndrome

JESPER HJORTNAES, ALE ALGRA, JOBIEN OLIJHOEK, MARGRIET HUISMAN, JOHANNES JACOBS, YOLANDA van der GRAAF, and FRANK VISSEREN, for the SMART Study Group

**ABSTRACT.** *Objective.* Gout and increased serum uric acid (SUA) levels are often seen in patients with components of the metabolic syndrome. Increased SUA levels are associated with increased vascular risk, as is the metabolic syndrome. We investigated the association between SUA levels and the metabolic syndrome in a population of patients with manifest vascular disease to determine whether SUA levels convey an independent risk for vascular disease in patients with the metabolic syndrome.

*Methods.* A nested case-cohort study of 431 patients with 220 cases with a new vascular event during followup, originating from the Second Manifestations of Arterial Disease (SMART) study. All patients had manifest vascular diseases, consisting of cerebral, coronary, or peripheral artery disease or abdominal aortic aneurysm. The relationship of SUA with the metabolic syndrome was analyzed with linear regression and adjusted for age, sex, creatinine clearance, and alcohol and diuretic use. The relationship of SUA levels with new vascular disease was investigated with Cox regression and adjusted for age and sex.

*Results.* The metabolic syndrome was present in 50% of patients. SUA levels were higher in 214 patients with the metabolic syndrome than in 217 patients without ( $0.36 \pm 0.08$  mmol/l vs  $0.32 \pm 0.09$  mmol/l). SUA concentrations increased with the number of components of the metabolic syndrome (0.30 mmol/l to 0.38 mmol/l) adjusted for age, sex, creatinine clearance, and alcohol and diuretic use. Increased SUA concentrations were independently associated with risk for vascular events in patients without the metabolic syndrome (age and sex adjusted hazard ratio 2.4, 95% CI 1.0–5.5), in contrast to patients with the metabolic syndrome (adjusted hazard ratio 1.9, 95% CI 1.0–3.9).

*Conclusion.* Elevated SUA levels are strongly associated with the metabolic syndrome, yet are not an independent risk factor for vascular disease in patients with the metabolic syndrome. In patients without the metabolic syndrome, elevated SUA levels are associated with increased risk for vascular disease. (First Release August 1 2007; J Rheumatol 2007;334:1882–7)

## Key Indexing Terms:

SERUM URIC ACID VASCULAR DISEASE METABOLIC SYNDROME EPIDEMIOLOGY

Clustering of vascular risk factors associated with central obesity is often referred to as the metabolic syndrome<sup>1,2</sup>, which is associated with an increased risk for the development of vascular disease, which could be explained by the individual components of the metabolic syndrome<sup>1,3,4</sup>. Although the exact underlying pathophysiology of the metabolic syndrome

remains unclear, insulin resistance has been found to play a major role<sup>5</sup>. Serum uric acid (SUA) is elevated in an insulin-resistant state, and increased levels of uric acid are associated with vascular disease<sup>6-10</sup>. It could therefore be hypothesized that increased SUA contributes to the increased risk for the development of vascular disease in patients with the metabolic syndrome. On the other hand, gout and increased SUA levels are typically seen in middle-aged, overweight patients with hypertension and hyperlipidemia, all components of the metabolic syndrome<sup>11</sup>, and these have recently been shown to be an independent risk factor for myocardial infarction<sup>12</sup>. It is unknown whether increased SUA levels further increase the elevated vascular risk in these patients with metabolic syndrome, and which component of this syndrome is most closely associated with increased SUA levels and gout.

Uric acid is the final breakdown product of dietary and endogenous purines and is generated by xanthine dehydrogenase (xanthine oxidase), primarily in the liver and intestine<sup>13</sup>. The relationship of SUA with vascular disease may be explained by several pathophysiological mechanisms, including oxidative stress, inflammation, endothelial dysfunction,

---

From the Department of Internal Medicine, Vascular Medicine Section; Julius Centre for Health Sciences and Primary Care; Department of Neurology, Rudolph Magnus Institute of Neuroscience; and Department of Rheumatology and Clinical Immunology, University Medical Centre, Utrecht, The Netherlands.

J. Hjortnaes, BSc; J. Olijhoek, MD; F. Visseren, MD, PhD, Department of Internal Medicine, Vascular Medicine Section; A. Algra, MD, PhD, Julius Centre for Health Sciences and Primary Care, Department of Neurology, Rudolph Magnus Institute of Neuroscience; M. Huisman, MD; J. Jacobs, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Centre; Y. van der Graaf, MD, PhD, Julius Centre for Health Sciences and Primary Care.

Address reprint requests to Dr. F.L.J. Visseren, Department of Internal Medicine, Section of Vascular Medicine, University Medical Centre Utrecht (UMCU), G02.402, Utrecht, The Netherlands.

E-mail: F.L.J.Visseren@umcutrecht.nl

Accepted for publication May 3, 2007.

---

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2007. All rights reserved.

and platelet adhesiveness<sup>7,14</sup>, which are all involved in atherogenesis. In addition, an elevated SUA level may elevate blood pressure, because of its effects on the renal interstitium<sup>13,15,16</sup>.

SUA is associated with established vascular risk factors such as hypertension, obesity, low levels of high-density lipoprotein cholesterol, hypertriglyceridemia, hyperinsulinemia, and impaired glucose tolerance<sup>5,6,8,10,17,18</sup>, which are all involved in the metabolic syndrome<sup>19-21</sup>. It has been proposed that the attendant compensatory hyperinsulinemia caused by insulin resistance may contribute to the pathogenesis of hyperuricemia through its renal effect<sup>10</sup>.

Controversy surrounds the role of SUA in vascular disease. Whether the relationship of SUA with vascular events is causal or interdependent or is merely an epiphenomenon remains unclear. Epidemiological studies have shown that elevated SUA levels are a strong predictor of increased risk of vascular events<sup>6,10,22-28</sup>, although an independent relationship has been refuted by other studies<sup>6,9,26</sup>.

We investigated the associations of SUA levels with individual components of the metabolic syndrome and explored whether an elevated SUA level is an independent risk factor for vascular disease in patients with manifest vascular disease, with and without the metabolic syndrome.

## MATERIALS AND METHODS

**Study population.** For this nested case-cohort study, data were used from patients enrolled in the Second Manifestations of Arterial Disease (SMART) Study, an ongoing prospective cohort study at the University Medical Center Utrecht, designed to establish the prevalence of concomitant arterial diseases and risk factors for vascular disease in a high-risk population<sup>29</sup>. The Medical Ethics Committee approved the study and all subjects gave their written informed consent before participating.

We examined data for 431 patients with clinical manifest arterial disease. Coronary artery disease included angina pectoris and myocardial infarction; cerebral vascular disease included transient ischemic attack, cerebral infarction, amaurosis fugax, and retinal infarction; peripheral artery disease included symptomatic and documented obstruction of distal arteries of the leg (Fontaine II and III) or abdominal aortic aneurysm. A total of 2398 patients with a history of vascular disease were enrolled in the SMART study between 1996 and 2003; 220 cases emerged who had had a new vascular event during followup. A random sample of 240 patients (10%) was drawn from the 2398 patients and served as a reference control group. Of these 240 patients, 16 had already been selected because of an outcome event. Hence, the study population consisted of 444 patients. Because blood samples of 13 patients were missing, analyses were carried out with the data of 431 patients.

**Definitions.** At the time of enrollment, clinical information was obtained with a standardized health questionnaire. Height, body weight, waist circumference, and blood pressure were measured. Fasting blood was sampled to determine lipid, serum glucose, creatinine, adiponectin, insulin, and uric acid concentrations. SUA levels were measured with an immunochemical assay (Vitros 250 Chemistry System, Johnson & Johnson Clinical Diagnostics, Rochester, NY, USA) Reference values for serum, male: 0.20–0.44 mmol/l; female: 0.14–0.34 mmol/l. Measurable range from 0.03 mmol/l to 1.01 mmol/l.

Metabolic syndrome was diagnosed according to the Adult Treatment Panel III criteria, including 3 or more of the following abnormalities: abdominal obesity (waist circumference > 102 cm in men and > 88 cm in women), high blood pressure ( $\geq$  130 mm Hg systolic or  $\geq$  85 mm Hg diastolic) or use of blood pressure-lowering agents, hypertriglyceridemia [serum triglycerides  $\geq$  1.70 mmol/l (150 mg/dl)], low HDL cholesterol [serum HDL cholesterol <

1.04 mmol/l (40 mg/dl) in men and < 1.29 mmol/l (50 mg/dl) in women], and high fasting glucose [fasting serum glucose  $\geq$  6.1 mmol/l (110 mg/dl)] or use of glucose-lowering agents<sup>21</sup>. Waist circumference was measured in participants entering SMART before January 1, 1999. If waist circumference was not available, a body mass index cutpoint of 30 kg/m<sup>2</sup> was used as criterion for obesity. Diabetes was defined as self-reported diabetes or the use of glucose-lowering agents or a fasting glucose  $\geq$  7.0 mmol/l in patients with no history of diabetes. History of vascular disease included atherosclerotic vascular diseases in the medical history other than the vascular diagnosis at inclusion. Current or past smoking included patients currently smoking and those who recently stopped or smoked in the past. A similar definition was used for current or past alcohol drinking. Renal function was determined with the Cockcroft-Gault formula<sup>30</sup>. Homeostasis model assessment of insulin resistance (HOMA-IR) was used as quantitative estimate of insulin resistance<sup>31</sup>.

Patients were asked biannually to complete a questionnaire on hospitalizations and outpatient clinic visits. Events of interest for this study were the occurrence of a composite of first vascular events, namely vascular death, ischemic stroke, and coronary ischemic event.

When a possible event was reported by the patient, hospital discharge letters and results of relevant laboratory and radiology examinations were collected. Based on this information, all events were audited by 3 members of the SMART study endpoint committee. This consisted of physicians from different departments. In case of disagreement, consensus was reached by consulting other members of the endpoint committee.

**Data analyses.** Data are presented as percentages with number of patients, as mean  $\pm$  standard deviation for normally distributed variables, and as median with interquartile range for non-normally distributed variables. Multiple linear regression analysis was performed to investigate the association of SUA with the metabolic syndrome and the relation of SUA with the number of metabolic syndrome components. The presence of the metabolic syndrome was taken as the dependent variable and SUA levels as independent; the relationships were adjusted for sex, age, renal function (Cockcroft-Gault), and alcohol and diuretic use. Cox proportional hazard regression models were used to investigate the relation of SUA levels with new vascular events in patients with and without the metabolic syndrome. Endpoint hazard ratio (HR) for each uric acid category was calculated with the lowest uric acid category as reference in patients without the metabolic syndrome. Results are presented as HR with corresponding 95% confidence intervals (CI); effect estimates were adjusted for age and sex. All statistical analyses were performed using the Statistical Package for the Social Sciences for Windows 11.1 (SPSS, Chicago, IL, USA), except for the Cox regression, which was performed using SAS.

## RESULTS

**Study population.** Baseline characteristics of the study population are presented in Table 1 according to tertiles of SUA. We identified 217 (50%) patients with metabolic syndrome and 214 (50%) patients without. Based on a cutoff point of 7.0 mg/dl (0.416 mmol/l)<sup>14</sup>, 32 (15%) patients without the metabolic syndrome and 52 (24%) with metabolic syndrome had hyperuricemia. Patients with the metabolic syndrome had a higher creatinine clearance (73 vs 70 ml/min). Differences were noted in fasting serum glucose concentrations (6.6 vs 5.5 mmol/l), adiponectin levels (4.2 vs 6.0  $\mu$ g/l), higher triglycerides (2.33 vs 1.23 mmol/l), and lower HDL-cholesterol levels (0.94 vs 1.26 mmol/l) in patients with compared to those without the metabolic syndrome. At baseline, previous clinical manifestations of atherosclerotic disease were equally distributed in both groups. Use of diuretics and use of other blood pressure-lowering medications were more frequently seen in patients with the metabolic syndrome.

Table 1. Baseline laboratory findings of study population based on uric acid tertiles.

Variable	Uric Acid Tertiles		
	1, n = 133	2, n = 155	3, n = 142
Serum uric acid, mmol/l <sup>a</sup>	0.25 ± 0.04	0.33 ± 0.02	0.44 ± 0.07
Male, %	61	80	86
Age, yrs <sup>a</sup>	62 ± 11	61 ± 11	64 ± 10
Body mass index, kg/m <sup>2</sup> <sup>a</sup>	25 ± 4	27 ± 4	27 ± 4
Smoking*, %	87	76	86
Alcohol drinking**, %	73	75	81
Creatinine clearance (Cockcroft), ml/min <sup>a</sup>	76 ± 20	74 ± 26	64 ± 24
Fasting serum insulin, mIU/l <sup>b</sup>	9 (7–13)	13 (8–18)	13 (9–19)
Adiponectin, µg/ml <sup>b</sup>	6.0 (3.6–8.9)	5.0 (3.4–7.9)	4.8 (3.1–7.8)
Use of lipid-lowering agents, %	42	37	36
Use of glucose-lowering agents, %	21	21	22
HOMA-IR <sup>†</sup>			
With metabolic syndrome	2.4 ± 2.3	2.6 ± 2.0	3.1 ± 3.4
Without metabolic syndrome	4.5 ± 2.6	4.6 ± 2.6	5.5 ± 5.3
Use of blood pressure-lowering agents			
Diuretics, %	6	14	32
Calcium antagonists, %	22	23	24
ACE inhibitors, %	22	19	31
Beta-blockers, %	35	41	46
Manifest vascular disease at baseline			
Peripheral artery disease, %	34	25	32
Cerebral vascular disease, %	38	35	29
Coronary artery disease, %	45	53	59
Abdominal aortic aneurysm, %	12	20	22
Components of metabolic syndrome			
Glucose, mmol/l <sup>b</sup>	5.7 (5.2–7.0)	6.0 (5.5–8.8)	5.9 (5.6–6.7)
Triglycerides, mmol/l <sup>b</sup>	1.48 (1.05–1.86)	1.67 (1.26–2.38)	1.85 (1.28–2.35)
HDL-cholesterol, mmol/l <sup>b</sup>	1.25 (1.05–1.46)	1.05 (0.91–1.32)	1.04 (0.88–1.23)
Waist circumference, cm <sup>a</sup>	91 ± 11	98 ± 13	100 ± 10
Systolic blood pressure, mmHg <sup>a</sup>	145 ± 25	148 ± 22	142 ± 20
Diastolic blood pressure, mmHg <sup>a</sup>	79 ± 11	82 ± 10	79 ± 11

<sup>a</sup> Mean ± standard deviation. <sup>b</sup> Median (interquartile range). \* Percentage of cases still smoking, recently stopped smoking, or previously smoking. \*\* Percentage of cases still drinking, recently stopped drinking, or previously drinking. <sup>†</sup> Homeostasis model assessment of insulin resistance. ACE: angiotensin-converting enzyme.

*Relation between uric acid plasma levels and the metabolic syndrome.* The relationship between uric acid and the metabolic syndrome is described in Table 2. The crude difference in uric acid levels between patients with and without the metabolic syndrome was 0.04 mmol/l (95% CI 0.02–0.06). Adjusting for age, sex, creatinine clearance, and use of alcohol and diuretics did not change these values essentially. We observed a gradual increase of SUA levels parallel to an increase in the number of components of the metabolic syndrome, in both crude and adjusted analyses.

Table 3 shows the relation between the individual components of the metabolic syndrome and uric acid. In particular, waist circumference (0.37 ± 0.09 vs 0.33 ± 0.09) and triglyceride levels (0.37 ± 0.08 vs 0.32 ± 0.09) were significantly associated with elevated uric acid levels after multiple adjustments.

*Uric acid and new vascular events in patients with and without metabolic syndrome.* The mean (± SD) SUA concentrations of each of these tertiles were 0.25 ± 0.04, 0.33 ± 0.02,

and 0.44 ± 0.07 mmol/l, respectively (Table 1). Age was equally distributed. The creatinine clearance decreased from 76 ± 20 to 74 ± 26 to 64 ± 24 ml/min from Tertile One to Tertile Three, respectively. Differences were seen in adiponectin levels (6.0 vs 5.0 vs 4.8 µg/ml), triglycerides (1.48 vs 1.67 vs 1.85 mmol/l), HDL-cholesterol (1.25 vs 1.05 vs 1.04 mmol/l), and waist circumference (91 vs 98 vs 100 cm). The use of diuretics and other blood pressure-lowering agents was seen predominantly in Tertile Three.

In patients without the metabolic syndrome there was an increase in HOMA-IR over the 3 tertiles of uric acid (mean ± SD: 2.4 ± 2.3, 2.6 ± 2.0, and 3.1 ± 3.4). In patients with the metabolic syndrome there seems to be a clear increase in insulin resistance only in the third tertile (mean ± SD: 4.5 ± 2.6, 4.6 ± 2.6, and 5.5 ± 5.3, respectively; Table 1).

In patients who did not have the metabolic syndrome, the adjusted hazard ratios for a vascular event are for Tertile Two 1.9 (95% CI 0.9–3.8) and for Tertile Three 2.4 (95% CI 1.0–5.5); Tertile One is reference (Table 4). In patients with

Table 2. Relation between uric acid and metabolic syndrome (defined by the ATP III criteria).

	N	Uric Acid, Crude	Δ (95% CI)	Uric Acid, Adjusted for Age and Sex	Δ (95% CI)	Uric Acid Adjusted for Age, Sex, Creatinine Clearance <sup>a</sup> Alcohol, Medication <sup>b</sup>	
						Δ (95% CI)	Δ (95% CI)
Metabolic syndrome							
No	217	0.32 ± 0.09	—	0.33 ± 0.09	—	0.33 ± 0.09	—
Yes	214	0.36 ± 0.08	0.04 (0.02–0.06)*	0.36 ± 0.08	0.04 (0.02–0.06)*	0.36 ± 0.08	0.04 (0.02–0.06)*
No. of components of metabolic syndrome							
0	25	0.30 ± 0.06	—	0.30 ± 0.06	—	0.30 ± 0.06	—
1	82	0.33 ± 0.08	0.04 (0.00–0.07)*	0.33 ± 0.08	0.04 (0.01–0.07)*	0.33 ± 0.08	0.03 (0.00–0.05)*
2	110	0.33 ± 0.09	0.03 (–0.01–0.07)	0.33 ± 0.09	0.03 (–0.01–0.07)	0.33 ± 0.09	0.03 (0.01–0.06)*
3	102	0.36 ± 0.09	0.07 (0.03–0.10)*	0.36 ± 0.09	0.06 (0.03–0.10)*	0.35 ± 0.10	0.05 (0.02–0.08)*
4	77	0.37 ± 0.10	0.07 (0.03–0.11)*	0.37 ± 0.10	0.07 (0.02–0.11)*	0.37 ± 0.10	0.07 (0.02–0.11)*
5	35	0.36 ± 0.09	0.06 (0.02–0.10)*	0.37 ± 0.09	0.06 (0.02–0.10)*	0.38 ± 0.09	0.07 (0.03–0.12)*

Data are means ± standard deviation. <sup>a</sup> Cockcroft-Gault formula. <sup>b</sup> Medication: adjusted for diuretics. \* p < 0.05.

Table 3. Relations between individual criteria of the metabolic syndrome (according to ATP III components) and uric acid levels.

	Uric Acid, Crude	Δ (95% CI)	Uric Acid, Adjusted for Age and Sex	Δ (95% CI)	Uric Acid Adjusted for Age, Sex, Renal Clearance <sup>a</sup> , and Diuretics	
					Δ (95% CI)	Δ (95% CI)
Waist circumference, cm						
No	0.34 ± 0.09	—	0.34 ± 0.09	—	0.33 ± 0.09	—
Yes	0.35 ± 0.09	0.01 (–0.01–0.03)	0.36 ± 0.09	0.02 (–0.01–0.04)	0.37 ± 0.09	0.04 (0.02–0.06)*
Blood pressure, mm Hg						
No	0.33 ± 0.09	—	0.33 ± 0.09	—	0.33 ± 0.09	—
Yes	0.35 ± 0.09	0.02 (–0.01–0.04)	0.35 ± 0.09	0.01 (–0.01–0.04)	0.35 ± 0.09	0.02 (–0.01–0.04)
HDL-cholesterol, mmol/l						
No	0.34 ± 0.09	—	0.34 ± 0.09	—	0.34 ± 0.09	—
Yes	0.35 ± 0.09	0.00 (–0.02–0.01)	0.35 ± 0.09	0.01 (–0.01–0.03)	0.35 ± 0.09	0.01 (–0.01–0.02)
Triglycerides, mmol/l						
No	0.32 ± 0.08	—	0.32 ± 0.08	—	0.32 ± 0.08	—
Yes	0.37 ± 0.09	0.04 (0.03–0.06)*	0.37 ± 0.10	0.05 (0.03–0.06)**	0.37 ± 0.10	0.04 (0.03–0.06)*
Glucose, mmol/l						
No	0.33 ± 0.08	—	0.33 ± 0.08	—	0.33 ± 0.08	—
Yes	0.36 ± 0.09	0.03 (0.01–0.04)*	0.36 ± 0.09	0.02 (0.01–0.04)**	0.36 ± 0.08	0.02 (0.02–0.04)*

Data are means ± standard deviation. Cutoff points of components: waist circumference: > 102 cm in men and > 88 cm in women; blood pressure: ≥ 130 mmHg systolic or ≥ 85 mmHg diastolic, HDL-cholesterol: serum HDL cholesterol < 1.04 mmol/l (40 mg/dl) in men and < 1.29 mmol/l (50 mg/dl) in women; triglycerides: serum triglycerides ≥ 1.70 mmol/l (150 mg/dl); fasting serum glucose: ≥ 6.1 mmol/l (110 mg/dl). <sup>a</sup> Cockcroft-Gault formula. \* p < 0.05.

the metabolic syndrome the hazard ratios are for Tertile One 1.9 (95% CI 0.8–4.2), Tertile Two 1.6 (95% CI 0.8–3.1), and Tertile Three 1.9 (95% CI 1.0–3.9), respectively. Tertile One of patients without the metabolic syndrome is used as reference.

## DISCUSSION

We found that elevated SUA levels were closely associated with the metabolic syndrome in patients with manifest vascular disease, and that increased SUA levels were associated with an increased vascular risk in patients without the metabolic syndrome. Patients with the metabolic syndrome showed significantly higher SUA concentrations compared to those without.

The observation that not all the individual components of

the metabolic syndrome are significantly associated with SUA, in addition to the relatively small difference in uric acid concentrations between the presence and absence of the criteria, emphasizes that the metabolic syndrome functions, and needs to be regarded, as a cluster of risk factors.

Although there are differences in uric acid levels between the presence and absence of individual metabolic syndrome criteria, waist circumference and triglycerides are the only criteria significantly related to uric acid levels in this population. This could be explained by the central role of insulin resistance. The attendant compensatory hyperinsulinemia, caused by insulin resistance, may contribute to the pathogenesis of increased serum uric acid through renal effects<sup>10</sup>. One hypothesis is that the kidneys are directly affected by rising insulin levels and that urinary uric acid clearance decreases in pro-

Table 4. Risk for cardiovascular events, according to uric acid levels.

Metabolic Syndrome	Uric Acid	Case	Control	Hazard Ratio*	95% CI
No, n = 217	Tertile 1	32	54	Ref	—
	Tertile 2	43	41	1.9	0.9–3.8
	Tertile 3	30	24	2.4	1.0–5.5
Yes, n = 214	Tertile 1	22	26	1.9	0.8–4.2
	Tertile 2	38	44	1.6	0.8–3.1
	Tertile 3	51	41	1.9	1.0–3.9

\* Adjusted for age and sex. Ref: reference.

portion to increasing insulin resistance, thus increasing SUA<sup>18</sup>. Studies have shown that an important contributor to the development of insulin resistance is an overabundance of circulating free fatty acids<sup>9,13,18</sup>. Plasma albumin-bound free fatty acids are derived mainly from adipose tissue triglyceride stores released through the action of the cyclic-AMP-dependent enzyme hormone-sensitive lipase<sup>13</sup>. Obesity, measured by waist circumference and indicated by an increase in abdominal adipose tissue, contributes to higher plasma concentrations of free fatty acids<sup>18</sup>.

Increased SUA levels are associated with elevated blood pressure, possibly through the generation of reactive oxygen species, impaired endothelial nitric oxide release, and subsequent endothelial dysfunction<sup>11</sup>. However, even though use of diuretics was considered as a confounder in our analysis, elevated uric acid levels were not associated with the presence of the ATP-III blood pressure criterion of the metabolic syndrome. This may be due to the extensive use of blood pressure-lowering agents other than diuretics in our study population. Interestingly, although the SUA concentrations in our study fall within the range of what are considered normal plasma concentrations, there is a significant cardiovascular risk associated with elevated uric acid concentrations. Hyperuricemia is usually defined as SUA concentrations > 6.5 or 7.0 mg/dl (0.39 or 0.42 mmol/l) in men and > 6.0 mg/dl (0.36 mmol/l) in women<sup>14</sup>.

Our study also documents that increased levels of SUA are independently associated with high vascular disease risk in patients without the metabolic syndrome, in contrast to patients with the metabolic syndrome in whom elevated SUA is not associated with an increased risk for vascular events. This may be explained by uric acid as a vascular risk factor already being accounted for by the presence of other risk factors clustering in the metabolic syndrome. SUA is so closely linked to insulin resistance that increased SUA concentrations do not lead to additional risk for vascular disease in these patients. Liao, *et al* documented that the ATP-III criteria show good specificity, and poor sensitivity for the presence of insulin resistance<sup>32</sup>. This poor sensitivity of ATP-III criteria for identifying insulin resistance could indicate that a significant number of patients are insulin-resistant but do not exhibit the metabolic syndrome trait complex. Thus patients who do not meet the ATP-III criteria could still be insulin-resistant.

Insulin resistance could therefore also explain the relation of SUA to cardiovascular risk in patients with no metabolic syndrome. Moreover, in each tertile of uric acid in patients without the metabolic syndrome a gradual increase in HOMA-IR can be seen, indicating a role for insulin resistance.

In addition, because of the association of SUA to insulin resistance<sup>13</sup> also observed in our study, one can make a case for adding elevated SUA levels as a criterion for the metabolic syndrome based on our findings. This could enable SUA to function as an additional marker within the definition of the metabolic syndrome for insulin resistance. Adding SUA to the current metabolic syndrome criteria, the predictive value for the diagnosis of insulin resistance and therefore the predictive value for new vascular disease may improve.

From our results it cannot be concluded whether SUA is a risk factor actively involved in atherogenesis or just an indicator of risk for vascular diseases. Our study population consisted of patients with clinical manifestations of arterial diseases and it is therefore unknown whether the results can be generalized to patients without clinically manifest arterial disease and non-survivors of vascular events. Although we have shown uric acid was independently associated with atherosclerotic disease in patients without the metabolic syndrome, prognostic studies are needed to assess the value of uric acid as a predictor of atherosclerotic disease in the context of other risk factors.

Elevated serum uric acid levels are strongly linked to the metabolic syndrome, but are not associated with an increased risk for vascular disease in patients with the metabolic syndrome. Increased serum uric acid levels are associated with increased risk for vascular disease in patients without the metabolic syndrome.

## REFERENCES

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005;365:1415-28.
2. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735-52.
3. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. *Circulation* 2005;111:1448-54.
4. Gorter PM, Olijhoek JK, Van der Graaf Y, Algra A, Rabelink TJ,

- Visseren FLJ. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebral vascular disease, peripheral arterial disease or abdominal aortic aneurysm. *Atherosclerosis* 2004;173:363-9.
5. Alderman MH, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. *Curr Med Res Opin* 2004;20:369-79.
  6. Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. *Arch Intern Med* 2004;164:1546-51.
  7. Alderman MH. Uric acid and cardiovascular risk. *Curr Opin Pharmacol* 2002;2:126-30.
  8. Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. *J Clin Endocrinol Metab* 1993;78:25-9.
  9. Wheeler JG, Juzwishin KDM, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis. *PLoS Med* 2005;2:e76.
  10. Lehto S, Niskanen L, Rönnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. *Stroke* 1998;29:635-9.
  11. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. *Curr Opin Rheumatol* 2006;18:193-8.
  12. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk for acute myocardial infarction. *Arthritis Rheum* 2006;54:2688-96.
  13. Johnson RJ, Kang D, Feig D, et al. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension* 2003;41:1183-90.
  14. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2004;67:1739-42.
  15. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. *Hypertension* 2004;45:28-33.
  16. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. *Nutrition Metab* 2004;1:10.
  17. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. *Stroke* 2003;34:1951-7.
  18. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and cardiovascular disease and death: the Framingham Heart Study. *Ann Intern Med* 1999;131:7-13.
  19. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality in the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. *JAMA* 2000;283:2404-10.
  20. Franse LV, Pahor M, Dibari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). *J Hypertens* 2000;18:1149-54.
  21. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
  22. Lee J, Sparrow D, Vokonas PS, Lansberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome: the Normative Aging Study. *Am J Epidemiol* 1995;142:288-94.
  23. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. *JAMA* 1991;266:3008-11.
  24. Reaven GM. The insulin resistance syndrome: Definition and dietary approaches to treatment. *Annu Rev Nutr* 2005;25:17.1-17.16.
  25. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol* 1995;141:637-44.
  26. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. *Acta Med Scand Suppl* 1982;688:45-9.
  27. Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricemia as a risk factor for cardiovascular disease and overall death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. *Acta Med Scand* 1988;224:549-55.
  28. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5 year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. *J Clin Epidemiol* 1989;42:257-67.
  29. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of arterial disease (SMART) study: rationale and design. *Eur J Epidemiol* 1999;5:773-81.
  30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41.
  31. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412-9.
  32. Liao Y, Kwon S, Shaughnessy S, et al. Critical Evaluation of Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. *Diabetes Care* 2004;27:978-83.